Inipharm commences dosing in INI-822 trial for MASH
Summary
Inipharm has started dosing patients in a 12-week proof-of-concept trial for its oral HSD17B13 inhibitor, INI-822, in metabolic dysfunction-associated steatohepatitis (MASH). The placebo-controlled, double-blind study plans to enroll about 50 patients and will assess safety, pharmacokinetics, tolerability, and biomarker changes. The company says the program has already shown encouraging target-engagement data after 28 days of dosing. Inipharm plans to use the results to support a move into Phase IIb studies.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected